Skip to main content
OpenTrials
Completed

NCT Number: NCT01905319

Juvenile Idiopathic Arthritis in Children in Estonia.

Aims of the study:

* to study the incidence rate of juvenile idiopathic arthritis (JIA) and it's clinical subtypes in Estonia for the years 1998-2000; * to examine the course and short-term clinical outcome of JIA.

Method: a prospective population-based study carried on in 14 counties of Estonia

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis
  • children aged 0-15 years who had arthritis of an unknown cause for at least six weeks with an onset of the disease during the study period

Exclusion criteria

  • Children with infectious arthritis, postinfectious arthritis, traumatic arthritis and systemic connective tissue diseases

Treatment and study plan

Blood collecting for storage of samples

Other

Primary outcomes

  1. Mean annual incidence rate of juvenile idiopathic arthritis in Estonia during years 1998-2000.

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

University of Tartu

Other

Registry information

Official study title

Juvenile Idiopathic Arthritis in Children in Estonia - an Epidemiological and Clinical Investigation.

Important dates

Study start
1998
Primary completion
2000
Study completion
2002
First posted
Jul 23, 2013
Registry last updated
Mar 25, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.